Biogen Inc. (BIIB) SEC Filings & Earnings Calls

Legacy MS portfolio continues to decline (-13% YoY), partially offsetting Growth Portfolio gains.

“MS product revenue $963M (-13% YoY); Legacy MS $767M.”

EPS significantly down due to deal-related charges and increased R&D investment; GAAP EPS $0.66 vs $4.33.

“GAAP diluted EPS $0.66 (down 85% YoY); Non-GAAP diluted EPS $3.60 (down 34% YoY).”

Apellis acquisition integration risk; expected dilution of $0.85 to Non-GAAP EPS in FY2026.

“Apellis acquisition expected ~$0.85 dilution to Non-GAAP diluted EPS for FY2026.”

Biosimilars revenue declining (-16% YoY) due to competitive pressure.

“Biosimilars revenue $153M (-16% YoY).”

Integration and Restructuring Risk

“For the three and six months ended June 30, 2026, we recognized approximately $153.2 million of net pre-tax restructuring charges, primarily consisting of employee severance costs and the acceleration of bonus payments that were subject to a double-trigger provision.” · word for word

Debt Increase

“Notes payable and term loan 7,290.3 6,286.8” · word for word

MS Franchise Decline

“Subtotal: Multiple Sclerosis 621.0 342.3 963.3 657.4 449.8 1,107.2” · word for word

Biosimilar Revenue Decline

“Subtotal: Biosimilars 0.1 152.7 152.8 2.5 179.2 181.7” · word for word

Large IPR&D charges reduce near-term EPS; Q2 charge $0.95/share, Q3 charge $1.75-$1.95/share.

“estimated charge is expected to impact GAAP and non-GAAP net income per diluted share for the second quarter of 2026 by approximately $0.95 per share” · word for word

Uncertainty in forecasting future IPR&D charges due to transaction timing and magnitude.

“Biogen does not forecast such acquired in-process research and development, upfront and milestone expense due to the uncertainty of the future occurrence, magnitude and timing of these transactions” · word for word

Integration risk of Apellis and SYFOVRE; CVR milestones may not be achieved; increased leverage from $2B term loan.

“CVR milestones require SYFOVRE net sales of $1.5B and $2.0B; no assurance milestones will be achieved. Leverage covenant at 3.75x.”

SPINRAZA revenue decline of 12% YoY due to timing of ex-U.S. shipments; MS portfolio flat.

“SPINRAZA global revenue of $374 million declined 12% year-over-year with ex-U.S. sales impacted by the timing of shipments.” · word for word

Full-year 2026 total revenue expected to decline by a mid-single digit percentage.

“Full year 2026 total revenue expected to decline by a mid-single digit percentage versus full year 2025.” · word for word

MS Franchise Generic Erosion

“TECFIDERA $109.5 million and $206.1 million.”

Contract Manufacturing Revenue Decline

“Contract manufacturing revenue $237.2 million and $282.3 million.”

Inventory Step-Up Amortization Pressure

“Amortization from the fair value step-up adjustment was approximately $107.6 million and $51.4 million, respectively.” · word for word

Apellis Acquisition Integration Risk

“We would pay Apellis shareholders $41.00 per share in cash, representing an expected total transaction value of approximately $5.6 billion.”

Low Say on Pay Support

“Following the 2025 Annual Meeting where our Say on Pay proposal received 67.7% support.” · word for word

PSU Payout Risk

“The 2023–2025 PSU cycle and the 2022–2024 PSU cycle also expired with $0 value delivered because we did not achieve the threshold performance required.” · word for word

MS Revenue Decline

“Total Revenue: This target, which declined compared to 2024, reflects continued erosion of MS revenues due to TECFIDERA generics in Europe and TYSABRI biosimilar entry timing and erosion.” · word for word

Growth Product Revenue Miss

“Growth Revenue: $2,411M achieved vs $2,551M target (75% of target)”

Uncertainty in final Q1 2026 results due to ongoing closing procedures

“Results for the quarter ended March 31, 2026, have not been finalized and are subject to our financial statement closing procedures” · word for word

Milestone Achievement Uncertainty

“There can be no assurance that any Milestone will be achieved prior to the expiration or termination of the CVR Agreement, or that payment will be required of Biogen with respect to any Milestone.” · word for word

Milestone Achievement Uncertainty

“There can be no assurance that any Milestone will be achieved prior to the expiration or termination of the CVR Agreement, or that payment will be required of Biogen with respect to any Milestone.” · word for word

Integration risk; CVR milestones may not be achieved.

“CVR payments contingent on SYFOVRE sales milestones; no assurance milestones will be achieved.”

Loss of key legal officer; temporary leadership gap.

“Departure of Chief Legal Officer; search initiated.”

Board chair departure, though orderly, introduces leadership transition risk.

“Caroline Dorsa... would not stand for re-election”

IRA Drug Pricing Impact

“we expect the IRA's drug pricing controls and Medicare Part D redesign to have an adverse impact on sales, particularly for our products that are more substantially reliant on Medicare reimbursement.” · word for word

Competition from generics/biosimilars

“Our products continue to face increasing competition from the introduction of new originator therapies, generics, prodrugs and biosimilars of existing products” · word for word

Dependence on collaborators

“We depend on relationships with collaborators and other third parties for revenue, and for the development, regulatory approval, commercialization and marketing of certain of our products and product candidates” · word for word

Revenue decline expected in FY2026 due to MS franchise erosion and biosimilars pressure.

“Expect full year 2026 total revenue to decline by a mid-single digit percentage versus full year 2025.” · word for word

Dependence on pipeline success for long-term growth; multiple late-stage readouts expected.

“10 additional potentially registrational studies across our pipeline expected to read out sequentially over the next four years.” · word for word

Uncertainty in final Q4 2025 results due to preliminary nature; charge may signal higher deal costs or pipeline investment.

“Results for the quarter ended December 31, 2025, have not been finalized and are subject to our financial statement closing procedures.” · word for word

MS franchise revenue decline

“Multiple Sclerosis product revenue declined 0.7% YoY (Q3: $1,061.5M vs $1,053.9M), with TECFIDERA down 27.7% and FAMPYRA terminated.”

Biosimilar revenue decline

“Biosimilar revenue declined 0.1% YoY (Q3: $196.8M vs $196.6M), with IMRALDI down 2.8% and BYOOVIZ down 12.5%.”

Contract manufacturing revenue decline

“Contract manufacturing revenue declined 36.2% YoY (Q3: $141.5M vs $221.9M).”

GAAP cost of sales increased as % of revenue due to TYSABRI royalty charge; contract manufacturing revenue declined 35%

“GAAP cost of sales 27% of revenue vs 26% prior year; contract manufacturing revenue $151M vs $232M, down 35%”